Estramustine Dose Compliance Predicts Recurrence in Very High-Risk Prostate Cancer

Neoadjuvant treatment before radical prostatectomy is an active area of prostate cancer research, particularly for patients whose disease has a high probability of extracapsular extension, nodal involvement, or postoperative biochemical recurrence. The reference study examined whether the amount of neoadjuvant estramustine phosphate actually received could help explain differences in outcome among men treated with a GnRH receptor antagonist and subsequent surgery. Its central contribution is not simply the use of combined chemohormonal therapy, but the finding that estramustine phosphate dose compliance may carry prognostic information in the very high-risk population.

Study Background and Research Question

The investigators focused on men with National Comprehensive Cancer Network high- or very high-risk, clinically localized prostate cancer classified as cTanyN0M0. Robot-assisted radical prostatectomy with lymph node dissection can be considered in selected patients with aggressive localized disease, but surgery alone does not reliably prevent recurrence. Androgen deprivation therapy can improve some pathological measures, yet its effect on long-term prognosis when used before surgery remains unsettled.

Japanese studies have reported potential benefit from neoadjuvant chemohormonal therapy combining low-dose estramustine phosphate with a GnRH agonist or antagonist. In the present study, the hormonal component was degarelix acetate, a selective GnRH receptor antagonist that suppresses GnRH-driven pituitary signaling and thereby supports androgen deprivation. The clinical question was whether completing the planned estramustine regimen affected biochemical recurrence-free survival after surgery, and whether this relationship differed between high-risk and very high-risk disease. The full design and results are reported in the International Journal of Urology reference study.

Key Innovation from the Reference Study

The study treats treatment exposure as an analyzable clinical variable rather than assuming that all patients assigned to neoadjuvant therapy receive an equivalent biological intervention. Of the patients who proceeded to surgery, most continued with two estramustine phosphate tablets, whereas a smaller group continued with one tablet. This created an opportunity to compare treatment completion with dose reduction in a real-world prospective cohort.

That distinction matters because dose reduction is rarely random. It can reflect anemia, liver enzyme abnormalities, thromboembolic events, cardiovascular risk, or other clinical factors that may also correlate with overall health and cancer biology. The investigators therefore did not establish that a lower dose directly caused recurrence. Instead, their multivariate analysis identified very high-risk classification and estramustine phosphate reduction as significant factors associated with biochemical recurrence. The signal was strongest in very high-risk disease, where the biochemical recurrence-free survival rate was significantly lower among patients whose dose was reduced.

This approach adds a practical dimension to cancer hormone therapy: treatment feasibility and adherence may influence the effectiveness observed in clinical practice. It also suggests that dose-intensity data should be retained in future neoadjuvant trials rather than reported only as treatment assignment.

Methods and Experimental Design Insights

This was a prospective clinical investigation conducted at the Clinical Investigation Department of Urology, Kobe City Medical Center General Hospital, between December 2017 and March 2023. Patients consented to six months of neoadjuvant chemohormonal therapy followed by robot-assisted radical prostatectomy. The investigators assessed treatment-related adverse events, perioperative outcomes, histopathological findings, and biochemical recurrence-free survival.

Protocol Parameters

• Study population: 187 men with NCCN high- or very high-risk cTanyN0M0 localized prostate cancer were prospectively enrolled, according to the reference report.
• Neoadjuvant duration: The planned treatment period was six months before robot-assisted radical prostatectomy.
• Hormonal component: Degarelix acetate was used as the GnRH antagonist component of the neoadjuvant regimen.
• Chemohormonal component: Low-dose estramustine phosphate was administered during the neoadjuvant period; the analysis distinguished continuation of two tablets from continuation of one tablet.
• Patient disposition: Thirty-six patients discontinued therapy before five months because of adverse events or other reasons. Eleven additional patients were excluded under a postoperative castration-range criterion reported by the investigators, leaving 140 patients who underwent surgery.
• Risk subgroup: Eighty-two surgical patients were classified as very high risk, allowing recurrence analyses to be stratified by baseline disease severity.
• Endpoints: The study evaluated adverse events, perioperative and histopathological outcomes, and biochemical recurrence-free survival, with multivariate analysis used to identify factors associated with recurrence.

For replication or secondary analysis, the most important methodological practice is to preserve a patient-level timeline linking planned dose, actual dose, interruption, reduction, discontinuation, adverse-event onset, surgery, and PSA follow-up. That recommendation is a workflow consideration rather than an additional dosing instruction from the study. Without this chronology, dose compliance can be difficult to distinguish from treatment intolerance or disease-related confounding.

Core Findings and Why They Matter

The treatment was not uniformly deliverable. Thirty-six of 187 enrolled patients stopped neoadjuvant therapy before five months, with adverse events accounting for 34 discontinuations and other reasons for two. Among the 140 patients who underwent surgery, 124 continued with two estramustine phosphate tablets and 16 continued with one. These numbers show that the tolerability profile affected the analyzable treatment exposure, an important consideration when interpreting neoadjuvant efficacy.

Pathological outcomes were significantly worse in the very high-risk group than in the high-risk group. This finding is clinically coherent with the underlying risk classification, but it also demonstrates why subgroup analysis was necessary: a regimen that appears useful in a mixed high-risk cohort may not provide the same degree of control in the most aggressive disease.

The principal prognostic result was that very high-risk status and estramustine phosphate dose reduction were significant factors in multivariate analysis. In the very high-risk subgroup, biochemical recurrence-free survival was significantly lower after dose reduction than after completion of the two-tablet regimen. The difference was not statistically significant in the high-risk subgroup. Thus, the study does not support a universal conclusion that any reduction predicts recurrence for every patient. Rather, it identifies a risk-dependent association that is most apparent when baseline tumor aggressiveness is already extreme.

The safety data provide an important explanation for why compliance deserves attention. Anemia was recorded in 174 patients, elevated transaminase levels in 68, and deep vein thrombosis in 24. Severe events included acute coronary syndrome in four patients and pulmonary embolism in three. These events are not merely background safety observations: they can trigger interruption or dose reduction, directly shaping the exposure variable used in the recurrence analysis. In practice, adverse-event surveillance is therefore connected to both patient safety and interpretation of treatment efficacy.

For endocrine oncology, the result complements the mechanistic logic of a GnRH receptor antagonist. Degarelix-mediated pituitary hormone regulation and androgen suppression provide the hormonal backbone, while estramustine phosphate adds the chemotherapy component. However, the study's prognostic signal is specifically about completion of the combined clinical regimen; it should not be simplified into a claim that receptor blockade alone determines recurrence.

Comparison with Existing Internal Articles

The internal article Testosterone Bounce in Degarelix-Treated Prostate Cancer examines longitudinal testosterone behavior as a possible prognostic marker in patients receiving degarelix acetate. Its focus differs from the reference study: testosterone trajectories represent a pharmacodynamic endocrine endpoint, whereas the current report evaluates estramustine phosphate dose compliance within neoadjuvant chemohormonal therapy. Together, the articles suggest that future studies could analyze both treatment exposure and serial hormone measurements, but the testosterone association requires prospective validation and cannot be used to reinterpret the present recurrence analysis.

A second relevant resource, Degarelix Acetate: From Stereochemistry to Assays, discusses how molecular stereochemistry and assay endpoint selection influence conclusions in receptor pharmacology. That perspective is complementary rather than interchangeable with the clinical study. The reference paper measures treatment delivery, pathology, adverse events, and PSA-defined recurrence; it does not directly measure GnRH receptor occupancy or cellular signaling. The comparison therefore helps researchers avoid treating a clinical dose-compliance result as if it were a receptor-binding assay result.

Limitations and Transferability

Several limitations constrain interpretation. First, the study was prospective but not randomized for estramustine dose. Patients receiving one tablet were likely different from those completing two tablets in ways related to toxicity, comorbidity, frailty, or treatment tolerance. Even with multivariate adjustment, residual confounding cannot be excluded. Dose reduction may therefore function partly as a marker of patient vulnerability rather than a direct biological cause of recurrence.

Second, only 16 of the 140 surgical patients continued with one tablet, and the number of dose-reduced patients within the very high-risk subgroup was smaller still. The significant subgroup association is clinically interesting but should be tested in larger, independently assembled cohorts. The report also comes from a Japanese clinical setting and a defined surgical pathway, so treatment selection, supportive care, and pathology practices may differ elsewhere.

Third, biochemical recurrence-free survival is an important postoperative endpoint but is not equivalent to metastasis-free survival, cancer-specific survival, or overall survival. The study also excluded patients who discontinued early and those meeting the reported postoperative castration-range criterion. Such exclusions may improve consistency of the surgical analysis while limiting generalizability to patients unable to complete neoadjuvant therapy.

Why this cross-domain matters, maturity, and limitations

The clinical findings can inform laboratory studies of GnRH receptor antagonism, pituitary hormone regulation, and hormone secretion inhibition, but the bridge is still exploratory. The reference study demonstrates an association between clinical estramustine exposure and postoperative recurrence; it does not prove a specific receptor-level mechanism for that association. Receptor-binding assays or pituitary and prostate cancer cell models could address pharmacology and endocrine response, but those experiments would test complementary questions rather than reproduce the clinical endpoint. Any translational interpretation should therefore preserve the distinction between exposure-response biology in cells and dose-compliance associations in surgical patients.

Research Support Resources

Researchers developing comparable receptor pharmacology, pituitary hormone regulation, or prostate cancer research workflows can use Degarelix acetate (SKU C8718) to support studies involving GnRH receptor antagonism and hormone secretion inhibition. The product information provides formulation, storage, and research-use guidance; those parameters should be optimized for the selected assay and should not be interpreted as a replacement for the clinical regimen evaluated in the reference study.